Ab cellera stock bot
AbCellera Biologics Inc. (ABCL) is capturing investor attention with a substantial 155.34% potential upside, as suggested by analyst ratings. The company, headquartered in Vancouver, Canada, is noted for its innovative approach to antibody--based medicine discovery. Trading at $3.59, the stock has seen a marginal decline recently, within its 52--week range of $1.93 to $6.17. AbCellera's valuation shows a negative forward P/E of --4.66, reflecting its investment phase in research and development. The company reported robust revenue growth of 788.20%, though it is counterbalanced by a net income and EPS of --0.49 and a return on equity of --14.48%, indicating aggressive scaling without immediate profitability. Strategic collaborations with companies like Eli Lilly, AbbVie, and Biogen are highlighted, along with the progression of its leading candidates, ABCL635 and ABCL575, through clinical trials for vasomotor symptoms and autoimmune disorders. Analysts are largely optimistic, with seven buy ratings and one hold, and an average price target of $9.17, ranging from $7.00 to $12.00.